EFFICACY AND SAFETY OF IBRUTINIB IN COMBINATION WITH RITUXIMAB AS FRONTLINE TREATMENT FOR INDOLENT CLINICAL FORMS OF MANTLE CELL LYMPHOMA. RESULTS OF THE GELTAMO IMCL‐2015 STUDY

Saved in:
Bibliographic Details
Published in:Hematological oncology 2021-06, Vol.39 (S2)
Main Authors: Giné, E., De la Cruz, F., Ubieto, A. Jiménez, Jiménez, J. López, García‐Sancho, A. Martín, Terol, M. J., González‐Barca, E., Casanova, M., De la Fuente Burguera, A., Niebla, A. Marín, Prat, A. Muntanola, González‐López, T. J., Aymerich, M., Setoain, X., Cortés‐Romera, M., Rotger, A., Medina, A., García‐Sanz, R., Campo, E., López‐Guillermo, A.
Format: Article
Language:English
Subjects:
Immunotherapy
Lymphoma
Mantle cell lymphoma
Monoclonal antibodies
Rituximab
Targeted cancer therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.60_2879